Physician profile
Mark Gohl
NPI 1902886500
$5,815.37
in general payments reported to CMS, 2019-2025
11 companies · $995 in 2025
The $995 reported for 2025 was more than what 99% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $473 · 2022: $814 · 2023: $2,426 · 2024: $1,107 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Consulting Fee: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,427.81 |
| Consulting Fee | $1,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,720.73 | 2021-2025 | |
| Edwards Lifesciences Corporation | $1,100.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $643.73 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.28 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Regeneron Healthcare Solutions, INC. | $274.12 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $241.51 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Intercept Pharmaceuticals, INC. | $166.67 | 2022-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $120.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $75.15 | 2021-2022 | |
| Boston Scientific Corporation | $63.07 | 2023 | |
| Redhill Biopharma INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.